Abstract
Endothelin-receptor blockade confers hemodynamic benefits in experimental and clinical heart failure. However, in a large placebo-controlled trial, the nonselective endothelinA+B receptor antagonist bosentan did not improve clinical symptoms or limit mortality ( Int J Cardiol 2002; 85:195). What about selective endothelinA-receptor antagonists? In a …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
